Iryna Drozd
Lisata Therapeutics (NASDAQ:LSTA) said its lead drug candidate LSTA1 has received Rare Pediatric Disease Designation from the FDA for the treatment of osteosarcoma, a rare cancer that can strike children and young adults.
The designation makes the company eligible to receive a Priority Review voucher for another product, if LSTA1 is approved for osteosarcoma. Lisata would be allowed to sell the voucher to another drug company.
LSTA1 also has FDA Orphan Drug Designation in the treatment of pancreatic cancer and glioblastoma multiforme.
The product is in Phase 2 testing for pancreatic cancer and various solid tumors, according to Lisata’s website.